BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 21698536)

  • 1. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAT--the new committee for advanced therapies at the European Medicines Agency.
    Celis P
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regulatory framework of innovative therapies : From bench to bedside].
    Walter C; Rohde B; Wicke DC; Pohler C; Lührmann A; von der Leyen H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):803-10. PubMed ID: 21698532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The Innovation Office of the Paul-Ehrlich-Institut. Regulatory support during the scientific development of ATMP].
    Ziegele B; Dahl L; Müller AT
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):857-66. PubMed ID: 21698540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European hospital exemption clause-new option for gene therapy?
    Buchholz CJ; Sanzenbacher R; Schüle S
    Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The certification of advanced therapy medicinal products. A quality label for product development in small and medium-sized enterprises].
    Berger A; Schüle S; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):816-21. PubMed ID: 21698534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical trials with advanced therapy medicinal products].
    Schüssler-Lenz M; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The advanced therapy classification procedure. Overview of experience gained so far.
    Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
    Carr M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
    Renner M; Anliker B; Sanzenbacher R; Schuele S
    Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products.
    Salmikangas P; Flory E; Reinhardt J; Hinz T; Maciulaitis R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):24-9. PubMed ID: 19940964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
    Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
    Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comprehensive assessment of ATMP. Difficulties and approaches].
    Thanner M; Nagel E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):843-8. PubMed ID: 21698538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.
    Schüle S; Renner M; Longhurst S; Narayanan G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):30-7. PubMed ID: 20012927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety monitoring of cell-based medicinal products (CBMPs)].
    Funk MB; Frech M; Spranger R; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges with advanced therapy medicinal products and how to meet them.
    ; ; Schneider CK; Salmikangas P; Jilma B; Flamion B; Todorova LR; Paphitou A; Haunerova I; Maimets T; Trouvin JH; Flory E; Tsiftsoglou A; Sarkadi B; Gudmundsson K; O'Donovan M; Migliaccio G; Ancāns J; Maciulaitis R; Robert JL; Samuel A; Ovelgönne JH; Hystad M; Fal AM; Lima BS; Moraru AS; Turcáni P; Zorec R; Ruiz S; Akerblom L; Narayanan G; Kent A; Bignami F; Dickson JG; Niederwieser D; Figuerola-Santos MA; Reischl IG; Beuneu C; Georgiev R; Vassiliou M; Pychova A; Clausen M; Methuen T; Lucas S; Schüssler-Lenz M; Kokkas V; Buzás Z; MacAleenan N; Galli MC; Linē A; Gulbinovic J; Berchem G; Fraczek M; Menezes-Ferreira M; Vilceanu N; Hrubisko M; Marinko P; Timón M; Cheng W; Crosbie GA; Meade N; di Paola ML; VandenDriessche T; Ljungman P; D'Apote L; Oliver-Diaz O; Büttel I; Celis P
    Nat Rev Drug Discov; 2010 Mar; 9(3):195-201. PubMed ID: 20190786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.